Abstract 3305
Background
Intratumoral injection of immunomodulating agents is a promising approach to prime antitumor immune responses and to control tumor growth while avoiding major systemic toxicities. Intratumoral CV8102, a TLR7/8/RIG-1 agonist based on noncoding single stranded RNA showed dose dependent single agent activity and synergism with PD-1 blockade in preclinical models.
Trial design
CV-8102-008 (NCT03291002) is a phase I, open-label, dose escalation and expansion study of intratumoral CV8102 in patients with advanced, inoperable cutaneous melanoma (cMEL), squamous cell carcinoma of the skin (cSCC) or head and neck (hnSCC) or adenoid cystic carcinoma (ACC). Eight intratumoral injections of CV8102 are provided over a 12 weeks period, unless disease progression requiring initiation of next-line therapy or unacceptable toxicity occurs. Patients showing evidence of clinical benefit on single agent CV8102 are eligible for further treatment. Currently the first part of the trial, with escalating doses of single agent CV8102 and CV8102 in combination with anti-PD-1 antibodies to determine the maximum tolerated/ recommended dose (MTD/RCD) guided by a Bayesian logistic regression model with overdose control. and flexible cohort sizes is ongoing. Safety, biological and tumor response according to RECIST 1.1/ir RECIST of CV8102 alone/in combination with anti-PD-1 antibodies will be further characterized in expansion cohorts including anti-PD-1 naïve and refractory patients.
Clinical trial identification
NCT03291002.
Editorial acknowledgement
Legal entity responsible for the study
CureVac AG.
Funding
CureVac AG.
Disclosure
J. Krauss: Advisory / Consultancy: Vaccibody; Advisory / Consultancy: Zelluna; Research grant / Funding (self): Heidelberg ImmunoTherapeutics. T. Eigentler: Advisory / Consultancy, Speaker Bureau / Expert testimony: MSD; Advisory / Consultancy, Speaker Bureau / Expert testimony: Roche; Advisory / Consultancy, Speaker Bureau / Expert testimony: Novartis; Advisory / Consultancy, Speaker Bureau / Expert testimony: Pierre Fabre; Advisory / Consultancy, Speaker Bureau / Expert testimony: Bristol-Myers Squibb. C. Weishaupt: Honoraria (institution), Advisory / Consultancy, Speaker Bureau / Expert testimony: Amgen; Honoraria (institution), Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (self): BMS; Honoraria (institution), Advisory / Consultancy, Speaker Bureau / Expert testimony: CureVac; Honoraria (institution), Advisory / Consultancy, Speaker Bureau / Expert testimony: La Roche Posay; Honoraria (institution), Advisory / Consultancy, Speaker Bureau / Expert testimony: Leo Pharma; Honoraria (institution), Advisory / Consultancy, Speaker Bureau / Expert testimony: MSD; Honoraria (institution), Advisory / Consultancy, Speaker Bureau / Expert testimony: Novartis; Honoraria (institution), Advisory / Consultancy, Speaker Bureau / Expert testimony: Pierre Fabre; Honoraria (institution), Advisory / Consultancy, Speaker Bureau / Expert testimony: Roche; Honoraria (institution), Advisory / Consultancy, Speaker Bureau / Expert testimony: Sanofi; Honoraria (institution), Advisory / Consultancy, Speaker Bureau / Expert testimony: Takeda. P. Terheyden: Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: BMS; Honoraria (self), Advisory / Consultancy: Novartis; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Pierre-Fabre; Honoraria (self), Advisory / Consultancy: Roche; Advisory / Consultancy: Sanofi; Advisory / Consultancy: Merck Serono; Honoraria (self): CureVac. L. Heinzerling: Advisory / Consultancy, Research grant / Funding (institution): Novartis; Advisory / Consultancy: Amgen; Advisory / Consultancy: MSD; Advisory / Consultancy: BMS; Advisory / Consultancy: Roche; Advisory / Consultancy: CureVac; Advisory / Consultancy: Pierre-Fabre; Advisory / Consultancy: Sanofi. P. Mohr: Advisory / Consultancy, Shareholder / Stockholder / Stock options: Pierre Fabre; Advisory / Consultancy, Research grant / Funding (institution), Shareholder / Stockholder / Stock options: Merck; Advisory / Consultancy, Shareholder / Stockholder / Stock options: Roche; Advisory / Consultancy, Shareholder / Stockholder / Stock options: GSK; Advisory / Consultancy, Research grant / Funding (institution), Shareholder / Stockholder / Stock options: BMS; Advisory / Consultancy, Shareholder / Stockholder / Stock options: Novartis; Advisory / Consultancy: LEO; Advisory / Consultancy, Shareholder / Stockholder / Stock options: Amgen. B. Weide: Advisory / Consultancy: CureVac GmbH; Advisory / Consultancy, Research grant / Funding (self): BMS; Advisory / Consultancy, Research grant / Funding (self): MSD. S. Ochsenreither: Honoraria (self), Advisory / Consultancy: MSD; Honoraria (self), Advisory / Consultancy: BMS; Honoraria (self), Advisory / Consultancy: Merck; Honoraria (self), Advisory / Consultancy: CureVac; Honoraria (self), Advisory / Consultancy: Glenmark; Honoraria (self), Advisory / Consultancy: Incyte. R. Gutzmer: Research grant / Funding (institution): Pfizer; Research grant / Funding (institution): Johnson&Johnson; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Novartis; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Amgen; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Merck-Serono; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Roche Pharma; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Bristol-MyersSquibb; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: MSD; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Almirall-Hermal; Honoraria (self), Travel / Accommodation / Expenses: AstraZeneca; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: SUN; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Pierre-Fabre; Honoraria (self), Advisory / Consultancy: LEO; Honoraria (self), Advisory / Consultancy: 4SC; Honoraria (self), Advisory / Consultancy: Incyte; Honoraria (self), Advisory / Consultancy: Takeda. J.C. Becker: Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony: Amgen; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (institution): Merck Serono; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony: Pfizer; Honoraria (self), Advisory / Consultancy: CureVac; Honoraria (self), Advisory / Consultancy: eTheRNA; Honoraria (self), Advisory / Consultancy: Lytix; Honoraria (self), Advisory / Consultancy: Novartis; Honoraria (self), Advisory / Consultancy: Rigontec; Honoraria (self), Advisory / Consultancy: Takeda; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: 4SC; Research grant / Funding (institution): Alcedis; Research grant / Funding (institution): Boehringer Ingelheim; Research grant / Funding (institution): Bristol-Myers Squibb; Travel / Accommodation / Expenses: Incyt. F. Funkner: Full / Part-time employment: CureVac AG. R. Heidenreich: Full / Part-time employment: CureVac AG. S. Kays: Full / Part-time employment: CureVac AG. U. Klinkhardt: Full / Part-time employment, Former: CureVac; Full / Part-time employment: Boehringer Ingelheim. U.S. Gnad-Vogt: Full / Part-time employment, Officer / Board of Directors: CureVac AG. B. Scheel: Full / Part-time employment: CureVac AG. O. Schönborn-Kellenberger: Full / Part-time employment, consultant to CureVac AG: Cogitars GmbH. T. Seibel: Full / Part-time employment: CureVac AG. All other authors have declared no conflicts of interest.
Resources from the same session
1842 - Immunological impact of surgery in NSCLC patients
Presenter: Akitoshi Yanagihara
Session: Poster Display session 1
Resources:
Abstract
4124 - The prognostic value of selected immunological panel in predicting the prognosis of early-stage resectable non-small cell lung cancer
Presenter: Sha Zhao
Session: Poster Display session 1
Resources:
Abstract
4468 - Genomic Heterogeneity and Clonality Analysis of Multiple synchronous lung cancers (MSLCs)
Presenter: Fachen Zhou
Session: Poster Display session 1
Resources:
Abstract
5547 - Analysis of immunosuppressive factors produced by tumorspheres in NSCLC. Prognostic value of Galectin-3 in adenocarcinoma
Presenter: Susana Torres Martinez
Session: Poster Display session 1
Resources:
Abstract
1658 - Frequency of epidermal growth factor receptor (EGFR) mutations in stage IB–IIIA EGFR mutation positive non-small-cell lung cancer (NSCLC) after complete tumour resection
Presenter: Masahiro Tsuboi
Session: Poster Display session 1
Resources:
Abstract
1535 - EGFR mutation is not a prognostic factor in completely resected lymph node–negative pulmonary adenocarcinoma (LNNPA)
Presenter: Nussara Leeladejkul
Session: Poster Display session 1
Resources:
Abstract
3262 - Prognostic significance of elements of the adaptive immunity in the microenvironment of early-stage non small cell lung cancer
Presenter: Aliki Liakea
Session: Poster Display session 1
Resources:
Abstract
4643 - Combined immunoscore for prognostic stratification of early stage NSCLC patients
Presenter: Giulia Pasello
Session: Poster Display session 1
Resources:
Abstract
4819 - Radiation-induced lung injury and misdiagnosis rate after SBRT
Presenter: Xiaolong Fu
Session: Poster Display session 1
Resources:
Abstract
681 - Significance of the red blood cell distribution width in resected pathological stage I non-small cell lung cancer
Presenter: Gouji Toyokawa
Session: Poster Display session 1
Resources:
Abstract